Trial Profile
A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Firtecan pegol (Primary)
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors Enzon Pharmaceuticals
- 29 Jan 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Jun 2012 Primary endpoint 'Recommended-phase-II-dose' has been met.
- 19 Jun 2012 Results have been presented at the 2012 Advances in Neuroblastoma Research Conference according to an Enzon Pharmaceuticals media release. Results were also summarised in the media release.